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Abstract
Introduction: Q fever is a zoonotic infection that may cause severe hepatitis. Q-fever hepatitis has
not yet been associated with autoimmune hepatitis and/or primary biliary cirrhosis.
Case presentation: We describe a 39-year-old man of Sri Lankan origin with chronic Q-fever
hepatitis who developed autoantibodies compatible with autoimmune hepatitis/primary biliary
cirrhosis overlap syndrome. Ursodeoxycholic acid in addition to antibiotic therapy markedly
improved hepatic enzyme levels suggesting that autoimmunity, potentially triggered by the underlying
infection, was involved in the pathogenesis of liver damage.
Conclusion: We suggest that Coxiella burnetii might trigger autoimmune liver disease. Patients with
Q-fever hepatitis who respond poorly to antibiotics should be investigated for serological evidence of
autoimmune hepatitis, primary biliary cirrhosis or overlap syndrome, as these patients could benefit
from adjunctive therapy with ursodeoxycholic acid. Conversely, C. burnetii serology might be
necessary in patients with autoimmune liver disease in order to exclude underlying Coxiella infection.
Introduction
Q fever is a zoonotic infection that may cause severe
hepatitis.Q-feverhepatitishasnotyetbeenassociatedwith
autoimmune hepatitis and/or primary biliary cirrhosis.
Case presentation
We report the case of a patient with chronic Q-fever
hepatitis with autoantibodies suggestive of autoimmune
hepatitis/primary biliary cirrhosis (AIH/PBC) overlap
syndrome. A previously healthy 39-year-old man of Sri
Lankan origin presented at the emergency department of
the university hospital of Lausanne, Switzerland in March
2005, complaining of fever, dry cough, nausea, vomiting,
and headache. The patient, who had lived in an urban area
of Switzerland without animal contact for the previous
17 years, had returned from a one month stay in rural
Sri Lanka 14 days before the onset of symptoms. On
physical examination, he was febrile at 39°C with stable
vital signs and no apparent site of infection. Laboratory
analyses showed normal leukocyte, hemoglobin and
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(117 μmol/L), C-reactive protein (75 mg/L), alanine
aminotransferase (ALAT, 120 U/L), gamma-glutamyl trans-
ferase(ү-GT,240 U/L)andbilirubin(27 μmol/L).Atestfor
malaria was negative. Lumbar puncture, chest X-ray and
abdominal ultrasound results were unremarkable. Treat-
ment with doxycycline was administered for 10 days for
presumptive leptospirosis with rapid resolution of clinical
signs and symptoms, but with persistently elevated liver
enzymes. Blood cultures remained sterile, and serology
was negative for leptospirosis, rickettsiosis, HIV and
hepatitis A, B and C. Q-fever serology was not carried out.
One month later, the patient’s symptoms recurred.
Serological testing was compatible with Q-fever in
transition from acute to chronic disease, with phase I
antibodies and high titers of phase II antibodies being
present (phase I: immunoglobulin (Ig)G, 1600; IgA, 80;
IgM,320;phaseII:IgG,25,600;IgA,640;IgM,640).Because
of the persistent hepatic cytolysis and cholestasis (ALAT
157U/L,ү-GT 546U/L), aliverbiopsywascarriedout which
revealed a mixed inflammatory infiltrate associated with
small non-necrotising epitheloidal cell granulomas without
giant cell formation, lipid vacuoles or fibrinoid rings. A
diagnosisof Q-feverhepatitiswasmade andthepatientwas
referred to our infectious diseases service in July 2005.
At this stage, the patient was afebrile and no longer had
cough, vomiting or headache, but complained of
persistent fatigue and intermittent right upper quadrant
abdominal pain. Hematological parameters, serum
creatinine, C-reactive protein and bilirubin were nor-
mal. Echocardiography showed normal systolic function
without valvular regurgitation or vegetations. Therapy
with doxycycline 200 mg/day and hydroxychloroquine
600 mg/day was initiated, with improvement in the
patient’s symptoms, hepatic enzyme values (ALAT 60 U/L,
ү-GT 179 U/L) and antibody titers against Coxiella
burnetii (phase I: IgG, 800; IgA, 0; IgM, 0; phase II: IgG,
1600; IgA, 0; IgM, 0) within 6 months of therapy
(Figure 1).
InMay2006,anacuteincreaseinhepatic enzymelevelswas
attributed to toxic hepatitis induced by either doxycycline
or hydroxychloroquine (ALAT 653 U/L, ү-GT 467 U/L).
A second liver biopsy, showing a mixed inflammatory
infiltrate with non-confluent hepatocellular necrosis and
without granulomas, supported the hypothesis of drug
toxicity. Interruption of doxycycline and hydroxychloro-
quine therapy resulted in a rapid improvement of hepatic
cytolysis and cholestasis (ALAT 63 U/L, ү-GT 252 U/L).
Treatment was temporarily withheld because of concerns
about repeated drug-induced liver injury.
Figure 1. Changes in hepatic enzyme levels and Q-fever serology over time and their correlation with therapy. Numbers on the
y-axis are x-fold of normal value (40 U/L for alanine aminotransferase; 70 U/L for gamma-glutamyl transferase). IgG G phase I/II:
IgG G antibodies against C. burnetii phase I and II antigen.
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remained stable, so we reintroduced antibiotic therapy
with levofloxacin 1g/day in November 2006. Given a
progressive discrepancy in ALAT and ү-GT levels (ALAT
85 U/L, ү-GT 451 U/L), the possibility of an additional
liver disease was considered. Abdominal ultrasound
showed a discrete hepatomegaly without dilatation of
the biliary tract. First-time screening for autoimmune liver
disease revealed smooth muscle antibodies (SMA)+++, an
antinuclear antibody (ANA) titer of 1:320, antimitochon-
drial antibodies (AMA)++, an anti-M2 antibody titer of
1:1140, and a total serum IgM level of 8.5 g/L (0.3-2.4 g/
L), consistent with autoimmune hepatitis/primary biliary
cirrhosis (AIH/PBC) overlap syndrome, which is a rare
condition in which patients have features of both diseases.
Hepatic cytolysis and/or cholestasis are present. Histolo-
gical findings may be non-specific or typical of either AIH
or PBC. Serology shows markers of AIH (ANA, SMA) and
of PBC (AMA, anti-M2 antibodies, elevation of total IgM
levels) [1,2]. Treatment consists of ursodeoxycholic acid
alone or in combination with corticosteroids [3]. In our
patient, a therapeutic trial with ursodeoxycholic acid was
initiated. While liver function tests had not improved after
1 month of levofloxacin (ALAT 80 U/L, ү-GT 596 U/L), a
dramatic decrease in both ALAT and ү-GT levels was
observed after 1 month of ursodeoxycholic acid (ALAT
27 U/L, ү-GT 147 U/L) therapy. By July 2007, with
ongoing levofloxacin and ursodeoxycholic acid treatment,
the patient had less fatigue and intermittent abdominal
pain. His liver enzymes were normal (ALAT 18 U/L, ү-GT
67 U/L), and antibody titers against C. burnetii had
decreased (phase I: IgG, 400; IgA, 0; IgM, 0; phase II:
IgG, 800; IgA, 0; IgM, 0). Levofloxacin therapy will be
continued until the phase I IgG titer is below 400, with a
minimum treatment duration of 18 months.
Discussion
We report the simultaneous presence of chronic Q-fever
hepatitis and autoimmune liver disease. Serology for
C. burnetii is highly specific, and we are not aware of any
reports of false-positive Q-fever serology in the context
of autoimmune disease. Moreover, liver enzymes and
C. burnetii serology clearly improved with antibiotic
therapy, leaving no doubt that our patient really had
Q-fever hepatitis.
Autoantibodies are commonly found in both acute and
chronic Q-fever [4,5]. Rheumatoid factor, ANA, AMA,
SMA, antiphospholipid antibodies, and a positive
Coombs test have been reported. It is not clear whether
these autoantibodies are an epiphenomenon without
clinical significance or if they are instrumental in the
pathogenesis of Q-fever. Levy et al. [6] described several
patients with acute Q-fever and positive SMA who
remained febrile despite adequate antibiotic treatment
and became afebrile with corticosteroid treatment, sug-
gesting a direct role of autoimmunity in causing the
patients’ illness. Our patient had autoantibodies compa-
tible with AIH/PBC overlap syndrome and his clinical and
laboratory condition strikingly improved following the
introduction of ursodeoxycholic acid, which improves
liver function in PBC without being beneficial for
cholestasis in general [7].
Our patient could simply have developed two rare
unrelated liver pathologies at once. Since he was com-
pletely asymptomatic before infection with C. burnetii,w e
do not believe that he had pre-existing AIH/PBC overlap
syndrome. However, one disease may have triggered the
other. AIH/PBC overlap syndrome as a trigger of Q-fever
hepatitis is not biologically plausible. On the other hand,
C. burnetii as a trigger of liver-directed autoimmunity
seems plausible. Many autoimmune diseases, such as
acute rheumatic fever and Guillain-Barré syndrome, are
believed to be induced by an infection through molecular
mimicry or immunomodulation [8]. Although AIH clearly
shows a genetic, human leukocyte antigen-linked predis-
position, there has been evidence implicating hepatitis
viruses, measles virus, cytomegalovirus and Epstein-Barr
virus as disease triggers [9]. Several features suggest a
causal relationship between PBC and infection, such as
case clustering within well-demarcated geographical areas
and an increased risk of recurrence after liver transplanta-
tion with increasing immunosuppression [10]. Escherichia
coli, atypical mycobacteria and retroviruses have been
implicated as causative agents. Roesler et al. [11] identified
a non-species-specific bacterial protein (b-subunit of
bacterial RNA polymerase) as an antibody target in AIH
and PBC, suggesting that not one, but many bacterial
species might potentially trigger liver-directed
autoimmunity.
To our knowledge, there are no reports in the literature
that suggest an association between Q-fever hepatitis and
autoimmune liver disease. We hypothesize that our
patient had Q-fever hepatitis at first, and when antibiotic
therapy was interrupted because of drug-induced hepatitis,
the sustained presence of C. burnetii in the liver triggered a
clinically relevant AIH/PBC overlap syndrome by mechan-
isms yet to be elucidated. Introduction of ursodeoxycholic
acid improved hepatic enzyme levels by acting on the
autoimmune component of liver disease, whereas
antibiotic therapy adequately treated the infectious
component, as demonstrated by decreasing antibodies
against C. burnetii.
Conclusion
C. burnetii might trigger autoimmune liver disease.
Patients with Q-fever hepatitis who respond poorly to
antibiotics should be investigated for serological evidence
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benefit from adjunctive therapy with ursodeoxycholic
acid. Conversely, C. burnetii serology might be worth
doing in patients with autoimmune liver disease in order
to exclude underlying Coxiella infection.
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